AVLAYAH brought in $3.6 million in its first quarter, as Denali advanced its Alzheimer’s pipeline and banked $195m from a voucher sale.
California-based Denali Therapeutics has posted its first quarterly revenue as a commercial-stage company, reporting $3.6 million in net product revenue from AVLAYAH (tividenofusp alfa-eknm) in the second quarter of 2026, its first full quarter on the US market [1].
AVLAYAH treats the neurologic manifestations of Hunter syndrome, or MPS II, a rare genetic disorder, and became the first FDA-approved medicine to use Denali’s Enzyme TransportVehicle (ETV) technology to cross the blood-brain barrier when it received accelerated approval in March.
If we look at it, $3.6 million is a small number for a company that lost $127.6 million in the same three months, but Denali executives say the underlying trend is encouraging. The company is guiding to $10.0 million to $12.0 million in AVLAYAH revenue for the third quarter, roughly triple the prior period, and says initial interest in starting treatment has outpaced its internal expectations. Roughly 80% of healthcare organisations that treat eligible MPS II patients have now been reached through launch webinars and field engagement.
Approval is not the same as access
The more instructive numbers for a rare-disease launch may be the payer figures rather than the revenue line, since regulatory approval does not automatically translate into patients being able to obtain, or afford, a therapy.
Published commercial policies now cover more than 50% of covered lives in the US, and 14 state Medicaid programmes have added AVLAYAH coverage. That is fast progress for a newly approved rare-disease therapy, though it also means roughly half of the potential commercial market has yet to formalise coverage, a gap Denali will need to close for revenue to scale toward consensus expectations.
A global Phase 2/3 study, COMPASS, is running alongside the launch and is intended to generate confirmatory evidence, support an expansion of the US label to adult patients, and underpin future regulatory filings outside the US.
Denali ended the quarter with roughly $940 million in cash, cash equivalents and marketable securities. In July, after the quarter closed, the company received $195 million in gross proceeds from selling a Priority Review Voucher it earned through the AVLAYAH approval, a mechanism biotech companies increasingly use to monetise rare-paediatric-disease designations without waiting on royalties or milestones.
On a pro forma basis, that brings Denali’s cash position to more than $1.1 billion, extending its runway as research and development spending, at $97.0 million for the quarter, continues to outstrip commercial revenue by a wide margin.
A pipeline still centred on the brain barrier
Beyond AVLAYAH, Denali advanced two additional TransportVehicle-enabled programmes into clinical development this quarter, both targeting Alzheimer’s disease: DNL628, an antisense oligonucleotide aimed at the MAPT gene, and DNL921, an antibody designed to target amyloid plaques. Initial data from both are expected in 2027.
The company also pushed back its expected readout for DNL593, a progranulin-replacement therapy for FTD-GRN developed with a now-departed partner, Takeda, to allow more time to observe biomarker changes; Takeda exited the collaboration in April for strategic reasons unrelated to the data.
Not every program moved forward. In May, Denali and Biogen discontinued DNL151, an LRRK2 inhibitor, in idiopathic Parkinson’s disease after the drug missed its primary and secondary endpoints in the Phase 2b LUMA study. Denali is continuing to test the same molecule independently in a genetically defined subset of Parkinson’s patients who carry a pathogenic LRRK2 variant, with data expected in the first half of 2027 – a reminder that even a validated delivery platform does not guarantee efficacy once a drug reaches the brain.
